arrow
S

Sylvain Manfrédi

Université de Bourgogne
H指数:37
被引数:5,752

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Fluoropyrimidine- versus Gemcitabine-Based Chemotherapy for Metastatic Recurrence After Resection of Ampullary Adenocarcinoma: a Real-World Analysis of the FFCD-AC Cohort

壶腹腺癌切除术后转移性复发的氟嘧啶类与吉西他滨为基础的化疗比较:FFCD-AC队列的真实世界分析

2026-10-090
OAAI
Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort)
2026-07-280
OA
Integrative analysis of circulating biomarkers of colorectal cancer combining mid-infrared spectroscopy and targeted metabolomics

结直肠癌循环生物标志物的整合分析:结合中红外光谱和靶向代谢组学

2026-05-080
OAAI
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer

5年CT扫描和CEA随访对结直肠癌患者生存终点的影响

2025-09-170
PRE
Real-World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort

阿特珠单抗–贝伐珠单抗在肝细胞癌中的真实世界结局:法国前瞻性CHIEF队列研究

2025-09-040
OAAI
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial

FOLFIRINOX或FOLFOX用于局部晚期或转移性小肠腺癌:PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA II期随机试验

2025-07-280
OAAI
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

TFOX与FOLFOX在HER2阴性晚期胃或胃食管结合部腺癌患者一线治疗中的比较(PRODIGE 51-FFCD-GASTFOX):一项开放标签、多中心、随机、III期临床试验

2025-04-230
PRE
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC

神经纤维瘤病1型(NF1)相关胃肠道间质瘤(GISTs)的临床描述及预后评分的开发:一项来自NETSARC的回顾性研究

2025-03-010
OAAI
Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line b evacizumab-base d chemotherapy in metastatic colorectal cancer

血清中红外光谱作为转移性结直肠癌一线b依达珠单抗-base d化疗新的预后指标的评价

2025-01-011
OAAI
PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA:一项II期随机试验,旨在评估mFOLFIRINOX和mFOLFOX方案在局部晚期或转移性小肠腺癌治疗中的效果。

2024-09-010
PRE
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
2024-05-142
PRE
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
2023-09-292
OAAI
Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors

多激酶抑制剂治疗失败后,阿特珠单抗联合贝伐单抗治疗晚期肝细胞癌

2023-07-014
OAAI